Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma - LARVOL DELTA

Effects of calcipotriene/betamethasone dipropionate foam combined with phototherapy in an imiquimod-induced mouse model of psoriasis (EADV 2026) - No abstract available

Preclinical • Dermatology • Immunology • Psoriasis

Paradoxical Immune Reactions under IL-17 Blockade: Insights from a Clinical Case Series (EADV-Sp 2026) - "Topical treatment with mometasone furoate ointment and keratolytic agents was initiated...Case 2: A 50-year-old female patient with a history of psoriatic arthritis (PsA) since 2021 and PV since 2022 was switched to ixekizumab in December 2022 after methotrexate (MTX) and apremilast proved ineffective...Topical treatment with calcipotriol and betamethasone dipropionate foam was prescribed, leading to a favorable clinical response...However, worsening of PV prompted a switch to adalimumab in August 2023, followed by a further switch to risankizumab in October 2024 due to fluctuating disease activity. Case 4: A 56-year-old woman with palmoplantar PV and autoimmune thyroiditis was started on ixekizumab in November 2025 after failure of MTX and topical therapies (betamethasone+calcipotriol and tazarotene)...Ixekizumab was discontinued, and treatment with topical steroids and systemic colchicine was initiated, resulting in marked improvement within two months...Conclusions..."

Clinical • Endocrine Disorders • Immunology • Inflammatory Arthritis • Plaque Psoriasis • Psoriasis • Psoriatic Arthritis • Pustular Psoriasis • Seronegative Spondyloarthropathies

Beyond Psoriasis: Recognizing Crusted Scabies in Patients with Communication Barriers (EADV-Sp 2026) - "Treatment with calcipotriol/betamethasone foam and systemic acitretin 20 mg/day was initiated...Biological therapy with adalimumab was then initiated; however, following the first administration, the patient developed a febrile fever and was diagnosed with pneumonia, necessitating the immediate cessation of the TNF-alpha inhibitor...Antiscabietic therapy was initiated with topical permethrin 5% for seven consecutive days, combined with oral ivermectin 200 micrograms/kg on days 1, 2, and 8. Following successful parasitic eradication, guselkumab was introduced to manage the underlying psoriasis...Treatment-resistant dermatosis in high-risk patients necessitates urgent diagnostic re-evaluation. Microscopic or histopathological screening is mandatory to optimize therapeutic outcomes, ensure the appropriate use of systemic agents, and maintain epidemiological safety within healthcare environments."

Clinical • Alzheimer's Disease • Atopic Dermatitis • Cognitive Disorders • Dermatitis • Dermatology • Dermatopathology • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lichen Planus • Lymphoma • Mental Retardation • Plaque Psoriasis • Pneumonia • Pruritus • Psoriasis • Respiratory Diseases • Seborrheic Dermatitis

LEO Pharma A/S…announced that China's National Medical Products Administration (NMPA) has approved Enstilar (calcipotriene/betamethasone dipropionate) to treat adult patients in China living with plaque psoriasis (Businesswire) - "The NMPA-approval is supported by results from a phase 3 trial comparing the efficacy and safety of a once daily application with Enstilar foam and Daivobet (calcipotriene/betamethasone) ointment after 4 weeks of treatment in adult Chinese subjects with stable plaque psoriasis (N=604)....Following the approval by the NMPA, the launch of Enstilar in China is planned for later this year."

China approval • Launch non-US • Psoriasis

Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial. (PubMed, Chin Med J (Engl)) - No abstract available

Journal • P3 data • Dermatology • Immunology • Psoriasis

Betamethasone-Calcipotriol Foam: A Promising Treatment for Erythema Annulare Centrifugum With LC-OCT Monitoring. (PubMed, Dermatol Pract Concept) - No abstract available

Journal • Dermatology

Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (clinicaltrials.gov) - P4 | N=12 | Active, not recruiting | Sponsor: Aarhus University Hospital | Trial completion date: Nov 2025 ➔ Jul 2026

Trial completion date • Cognitive Disorders • Dermatology • Immunology • Psoriasis • Rheumatology

Combining narrowband UVB phototherapy with calcipotriol and betamethasone dipropionate foam modulates dendritic cell activity in psoriasis skin (EADV 2025) - "These findings suggest that the superior clinical efficacy of combining NB-UVB with Cal/BD foam may reflect dendritic cell modulation in psoriasis plaques."

Dermatology • Immunology • Psoriasis • CD1a • CD1C • HLA-DQB1 • HLA-DQB2 • ITGAX

Management of persistent psoriasis lesions using calcipotriol/betamethasone foam combitherapy: Real-world evidence case series from France (EADV 2025) - "Our insight into treatment combinations of Cal/BD foam may present an opportunity to improve standard care and patient satisfaction for hard-to-treat and persistent psoriasis lesions."

Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders • Dermatology • Immunology • Psoriasis • Sleep Disorder

psowyn: Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream (clinicaltrials.gov) - P=N/A | N=30 | Completed | Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Not yet recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis

Management of Persistent Psoriasis Lesions Using Calcipotriol/Betamethasone Foam Combitherapy: Real-World Evidence Case Series from France. (PubMed, Dermatol Ther (Heidelb)) - "Our insight into treatment combinations of Cal/BD foam may present an opportunity to improve standard care and patient satisfaction for hard-to-treat and persistent psoriasis lesions."

HEOR • Journal • Real-world evidence • CNS Disorders • Dermatology • Immunology • Psoriasis • Sleep Disorder

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa-case report, review of the literature and multidisciplinary clinical practice recommendations. (PubMed, Ther Adv Hematol) - "Ropeginterferon alfa-2b has been approved for patients with polycythemia vera (PV) with no symptomatic splenomegaly as first-line cytoreductive therapy, based on the results of the PROUD-PV/CONTINUATION-PV studies, documenting significantly higher rates of complete hematologic response (CHR) compared with hydroxyurea from 2-year timepoint onward...The other patient developed widespread psoriatric skin lesions, which were treated with moderate effect with topical therapy with calcipotriene and betamethasone dipropionate foam, antidry calm lotion and in the course of the disease with ultraviolet light therapy (UVB). Only with methotrexate she achieved a nearly complete remission of the psoriasis...We review the pertinent literature on the management of interferon-mediated autoimmune diseases in patients with MPN. As there is little published evidence on that topic, we propose multidisciplinary clinical practice recommendations based on available evidence and clinical..."

Journal • Dermatology • Hematological Disorders • Immunology • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Psoriasis • Sarcoidosis

A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (clinicaltrials.gov) - P2 | N=50 | Completed | Sponsor: LEO Pharma | Phase classification: P2a ➔ P2

Phase classification • Dermatology • Immunology • Psoriasis • Rheumatology

Anti-tumor necrosis factor-alpha inhibitor-induced linear psoriasis: A case report. (PubMed, SAGE Open Med Case Rep) - "A clinical diagnosis of linear psoriasis was made, and the patient's dosage interval of infliximab was decreased to every 6 weeks. This case illustrates the potential for Betamethasone diproprionate/calcipotriol (Enstilar) topical foam use as a treatment approach for anti-tumor necrosis factor-alpha inhibitor-induced linear psoriasis. At present there is no consensus on linear psoriasis pathogenesis or best treatment approach, therefore, more research is needed to understand its pathogenesis and establish management guidelines."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Oncology • Psoriasis

Fixed-dose combination of calcipotriene/betamethasone dipropionate foam for the management of mild-to-moderate psoriasis in daily clinical practice: a collection of clinical experiences. (PubMed, Drugs Context) - "A group of experts discussed the value of the Cal/BD foam as a topical treatment for mild-to-moderate psoriasis in combination with systemic treatments. The reported experiences support effectiveness of the Cal/BD foam in daily clinical practice, with an improvement in patient quality of life."

Journal • Dermatology • Immunology • Psoriasis

Aggressive mycosis fungoides with large cell transformation and cerebral involvement (ADO 2024) - "The patient had previously been treated externally for psoriasis vulgaris with calcipotriol/betamethasone foam...The therapy was then switched to mogamulizumab (4 cycles), which resulted in further progression. Chemotherapy with gemcitabine was initiated to quickly reduce the tumor burden...This case shows that a manifestation of the CNS should be considered, especially in the case of large cell transformation and neurological symptoms. In addition to a radiological examination, a lumbar puncture should also be performed in order to initiate CNS-targeted therapy at an early stage."

CNS Disorders • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Gastroenterology • Gastrointestinal Disorder • Immunology • Mycosis Fungoides • Oncology • Peptic Ulcer • Pruritus • Psoriasis • Rheumatology

Drugs for plaque psoriasis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review • Dermatology • Immunology • Psoriasis

Comparison table: Some drugs for plaque psoriasis. (PubMed, Med Lett Drugs Ther) - No abstract available

Clinical • Journal • Dermatology • Immunology • Psoriasis

Psoriasis during natalizumab treatment for multiple sclerosis (EADV 2024) - "The patient was initiated on daily calcipotriene and betamethasone dipropionate foam, resulting in excellent clinical response. The association between natalizumab and psoriasis has been increasingly recognized in recent years. Natalizumab acts by inhibiting the migration of immune cells, particularly T cells, into the central nervous system, thereby reducing inflammation in multiple sclerosis. However, this mechanism of action may also lead to dysregulation of immune responses in the skin, predisposing patients to the development of psoriasis or exacerbation of pre-existing disease."

CNS Disorders • Dermatology • Dermatopathology • Immunology • Inflammation • Multiple Sclerosis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Psoriasis

Effectiveness and safety of deucravacitinib combined with calcipotriene/betamethasone dipropionate for treating moderate to severe plaque psoriasis (EADV 2024) - "Enstilar (calcipotriene 0.005%/betamethasone dipropionate 0.064%; C/BD) , a topical foam, is also approved to treat plaque psoriasis. Adding daily tapinarof cream to an existing biologic was tolerable and helped patients achieve the NPF treatment goal. This approach may prevent the need for switching biologics when patients do not respond, preserving the safety and cost associated with their current biologic."

Clinical • Dermatology • Immunology • Psoriasis • TYK2

Tumor necrosis factor-alpha inhibitor-associated psoriatic alopecia and palmoplantar pustulosis in a patient with ulcerative colitis (EADV 2024) - "We report a 29 - year - old woman who developed TiAPA and palmoplantar pustulosis after 6 months of treatment with infliximab for ulcerative colitis. Patient was switched out of class to ustekinumab after discontinuation of infliximab. Treatment was escalated with the addition of UVB phototherapy and topical therapy (calcipotriol/betamethasone dipropionate foam, emollient and keratolytic agent – urea) ."

Clinical • Alopecia • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Psoriasis • Rheumatoid Arthritis • Rheumatology • Ulcerative Colitis

LEO Pharma Submits New Drug Application for Enstilar for Adults with Plaque Psoriasis in China (Businesswire) - "LEO Pharma A/S, a global leader in medical dermatology, has today announced its submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for Enstilar (LEO 90100) to treat adult patients living with plaque psoriasis....The NDA submission is supported by results from a phase 3 trial comparing the efficacy and safety of a once daily application with Enstilar and Daivobet ointment after 4 weeks of treatment in adult Chinese subjects with stable plaque psoriasis (N=604)....Following the Enstilar submission, the Centre for Drug Evaluation (CDE) will validate the filing, before the full evaluation of the NDA is conducted by the CDE. The regulatory review process is expected to conclude in the first half of 2026."

China filing • Psoriasis

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris (clinicaltrials.gov) - P2 | N=35 | Completed | Sponsor: LEO Pharma | Phase classification: P2a ➔ P2

Phase classification • Dermatology • Immunology • Psoriasis • Rheumatology

Case Report of Patient with Eosinophilic Annular Erythema secondary to Rheumatological Disorder (EADV-Sp 2024) - "He received an initial diagnosis of psoriasis and received treatment in the form of Dobovet and Enstilar... EAE is a rare condition in which you can get these changes including lots of eosinophils in the skin biopsy. EAE is also associated with rheumatological disorders. This clinical picture adds up given his recent diagnosis and treatment of Polymyalgia Rheumatica."

Case report • Clinical • Dermatitis • Dermatology • Dermatopathology • Eosinophilia • Giant Cell Arteritis • Hematological Disorders • Musculoskeletal Pain • Pain • Pruritus • Psoriasis • Rheumatology

A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar®) in the management of psoriasis with scalp involvement. (PubMed, Drugs Context) - "The findings from these studies show that Cal/BD aerosol foam is rapidly effective, improves skin condition, alleviates symptoms such as itch, and has a positive impact on patient quality of life. These attributes address several unmet needs for patients with psoriasis with scalp involvement and have the potential to improve individual adherence to treatment."

Journal • Review • Dermatology • Immunology • Psoriasis